Skip to main content
← All trials
BronchiectasisDrugPhase 2

What this study is

This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.

What's being tested

  • GSK3862995B

    Intervention · DRUG

    Participants will be administered with dose level 1 of GSK3862995B.

  • Placebo

    Intervention · DRUG

    Participants will be administered with matching placebo.

Study details

Official title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis
Sponsor
GlaxoSmithKline
Conditions
Bronchiectasis
Enrolling
363 people
Starts
2025-10-30
Est. completion
2027-12-10
Design
Double-blind, randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗